Tower Research Capital LLC (Trc) Acurx Pharmaceuticals, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,065 shares of ACXP stock, worth $1,755. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,065
Previous 4,138
50.1%
Holding current value
$1,755
Previous $9,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ACXP
# of Institutions
26Shares Held
1.25MCall Options Held
9.3KPut Options Held
9.7K-
Vanguard Group Inc Valley Forge, PA529KShares$449,9460.0% of portfolio
-
Prospect Financial Services LLC Melville, NY295KShares$250,8130.35% of portfolio
-
Geode Capital Management, LLC Boston, MA147KShares$124,5250.0% of portfolio
-
Morgan Stanley New York, NY46.2KShares$39,2700.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC44.8KShares$38,0630.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $9.82M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...